Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2011: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2010: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Research Abstract |
The number of patients with chronic kidney disease(CKD) requiring dialysis therapy is increasing. ONO-1301 is a long-acting prostacyclin(PGI2) agonist and possesses thromboxane A2 synthase inhibitory effects. In the present study, therapeutic effects of ONO-1301 on tubulointerstitial injuries and diabetic nephropathy mediated via anti-fibrotic, anti-inflammatory and via inducing HGF, were observed, suggesting the potential of ONO-1301 in suppressing the progression of CKD.
|